Apellis Pharmaceuticals Inc. shareholders who sued the drugmaker’s leadership for allegedly concealing the safety risks of a blindness-prevention drug are dropping their suit following Biogen Inc.'s $5.6 billion acquisition of the company.

Optimum Communications reached a deal to raise capital at a unit that moves assets out of the reach of lenders that were sued by the company, in a move the troubled telco operator said will boost the chances of reaching a debt-overhaul agreement with the creditor group.

A former mergers and acquisitions lawyer with top firms including Latham & Watkins and Goodwin Procter pleaded not guilty to charges that he led a massive insider trading ring that made tens of millions of dollars in illegal profits.

Michael Darby joined Paul, Weiss, Rifkind, Wharton & Garrison as a partner in its M&A group within the Corporate Department, the firm announced Monday.

For leveraged finance practitioners, artificial intelligence is the only game in town — especially in the absence of more debt deals to finance mergers and acquisitions.

Anthropic PBC has confidentially submitted draft paperwork for a public listing, potentially leapfrogging longtime rival OpenAI in the race toward a Wall Street debut as soon as this fall.